Clinical trial
Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
NCT00300781 · Puma Biotechnology, Inc., Industry · Completed
Key facts
| NCT number | NCT00300781 |
|---|---|
| Title | Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer |
| Official title | Phase 2 Study of HKI-272 In Subjects With Advanced Breast Cancer |
| Lead sponsor | Puma Biotechnology, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Neoplasms, Neoplasms |
| Intervention type | Drug |
| Interventions | neratinib |
| Enrollment | 136 |
| Start date | Aug 4, 2006 |
| Primary completion | Apr 1, 2008 |
| Completion | Jan 30, 2018 |
| First posted | Mar 9, 2006 |
| Last update posted | Aug 14, 2018 |
| Countries | Belgium, China, France, India, Mexico, Russia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: